Genomics

Dataset Information

51

Gene expression profiling of experimental-induced pulmonary fibrosis in subcutaneous bleomycin-treated mice vs EXT-treated mice


ABSTRACT: Analysis of whole genome gene expression levels in distal lung tissue from mice with systemically bleomycin-induced pulmonary fibrosis. The hypothesis is that bleomycin promotes a specific genotype associated with development of pulmonary fibrosis and that treatment with compound EXT reduces the induction of genes related to the early progression of fibrosis. Overall design: Total RNA was isolated from distal lung tissue after 2 weeks s.c. treatment with bleomycin, with or without p.o. treament with EXT5 or EXT9. Comparisons of gene expression levels were made with healthy controls vs bleomycin-treated mice, with or without EXT-treatment. 6 mice (biological replicates) per treatment group were analyzed. Data were presented from two Ilumina microarray analyses with samples 1-7 and 8-14 included in first run. Second run contained samples 22-27 and 36-42, along with samples 3, 5, 7, 12 and 14 (re-analyzed) for the verification of non existing interassay variation. Data were presented as combined data from two seperate arrays. The arrays and analysis were performed by SCIBLU Genomics facility, Lund University (Lund, Sweden) and NBIS (National Bioinformatics Infrastructure Sweden).

INSTRUMENT(S): Illumina MouseWG-6 v2.0 expression beadchip

SUBMITTER: Anna Löfdahl  

PROVIDER: GSE103511 | GEO | 2017-09-06

SECONDARY ACCESSION(S): PRJNA401760

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
GSE103511_RAW.tar Raw
GSE103511_non-normalized.txt.gz Txt
filelist.txt Txt
Items per page:
1 - 3 of 3
altmetric image

Publications

Pulmonary fibrosis in vivo displays increased p21 expression reduced by 5-HT2B receptor antagonists in vitro - a potential pathway affecting proliferation.

Löfdahl Anna A   Rydell-Törmänen Kristina K   Larsson-Callerfelt Anna-Karin AK   Wenglén Christina C   Westergren-Thorsson Gunilla G  

Scientific reports 20180131 1


Serotonin (5-hydroxytryptamine) has repeatedly been associated with the development of fibrotic disorders such as pulmonary fibrosis. By blocking the binding of 5-HT to 5-HT2B receptors with receptor antagonists, several pro-fibrotic mechanisms can be inhibited. Bleomycin-induced pulmonary fibrosis is a model used to evaluate pathological mechanisms and pharmacological interventions. Previously we have shown attenuated fibrosis in systemic bleomycin-treated mice following treatment with two 5-HT  ...[more]

Similar Datasets

2019-01-01 | S-EPMC6547529 | BioStudies
2018-01-01 | S-EPMC6299094 | BioStudies
2018-01-01 | S-EPMC5792547 | BioStudies
2018-01-01 | S-EPMC5902212 | BioStudies
2015-01-01 | S-EPMC4586046 | BioStudies
1000-01-01 | S-EPMC5587549 | BioStudies
1000-01-01 | S-EPMC4656197 | BioStudies
2015-01-01 | S-EPMC4667265 | BioStudies
2017-01-01 | S-EPMC5363213 | BioStudies
2009-01-01 | S-EPMC2742760 | BioStudies